NEW YORK, NY / ACCESSWIRE / August 9, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Ocugen, Inc. (NASDAQ:OCGN)
Class Period: February 2, 2021 - June 10, 2021
Lead Plaintiff Deadline: August 17, 2021
The OCGN lawsuit alleges Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in OCGN: https://www.kleinstocklaw.com/pslra-1/ocugen-inc-loss-submission-form?id=18355&from=1
Home Point Capital Inc. (NASDAQ:HMPT)
This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.
Lead Plaintiff Deadline: August 20, 2021
The complaint alleges that throughout the class period Home Point Capital Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.
Learn about your recoverable losses in HMPT: https://www.kleinstocklaw.com/pslra-1/home-point-capital-inc-loss-submission-form?id=18355&from=1
Ardelyx Inc. (NASDAQ:ARDX)
Class Period: August 6, 2020 - July 19, 2021
Lead Plaintiff Deadline: September 28, 2021
During the class period, Ardelyx Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
Learn about your recoverable losses in ARDX: https://www.kleinstocklaw.com/pslra-1/ardelyx-inc-loss-submission-form?id=18355&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/658934/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-OCGN-HMPT-and-ARDX
